Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.
Lipoarabinomannan (LAM) is a component of the mycobacterial surface which has been associated with a variety of deleterious effects on immune system function. Despite the importance of LAM to the pathogenesis of mycobacterial infection, there is no information available on its fate in vivo. In this study, we determined the pharmacokinetics and tissue distribution of exogenously administered LAM in mice. For measurements of serum and tissue LAM concentrations, we developed an enzyme-linked immunosorbent assay which used monoclonal antibodies of different isotypes to capture and detect LAM at concentrations of >/=0.4 microg/ml. Intravenous administration of LAM to mice resulted in transient serum levels with organ deposition in the spleen and in the liver. Immunohistochemical studies localized LAM to the spleen marginal zone macrophages and, to a lesser degree, to liver macrophages. When LAM was administered to mice previously given a LAM-binding immunoglobulin M (IgM), LAM was very rapidly cleared from circulation. In those mice, deposition of LAM in the spleen was significantly reduced while LAM deposition in the liver increased. Administration of LAM-binding IgM resulted in significant levels of IgM to LAM in bile consistent with an increased hepatobiliary excretion of LAM in the presence of specific antibody. Bile, liver extracts, and bile salts were found to rapidly inactivate the immunoreactivity of LAM. The results indicate that serum clearance and organ deposition of LAM in mice are affected by the presence of LAM-binding antibody and suggest a mechanism by which antibody could modify the course of mycobacterial infection.
Glatman-Freedman
A
A
Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, New York 10461, USA. afreedma@aecom.yu.edu
Mednick
A J
AJ
Lendvai
N
N
Casadevall
A
A
D000818:Animals; D000907:Antibodies, Bacterial / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000378:metabolism; D000942:Antigens, Bacterial / Q000097:blood / Q000378:metabolism*; D001646:Bile / Q000276:immunology / Q000382:microbiology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D007075:Immunoglobulin M / Q000378:metabolism*; D007150:Immunohistochemistry; D008070:Lipopolysaccharides / Q000097:blood / Q000276:immunology* / Q000378:metabolism*; D008099:Liver / Q000276:immunology / Q000382:microbiology; D008657:Metabolic Clearance Rate; D051379:Mice; D008807:Mice, Inbred BALB C; D009169:Mycobacterium tuberculosis / Q000276:immunology* / Q000472:pathogenicity*; D014018:Tissue Distribution; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; C050016:lipoarabinomannan